Advances in Endometrial Cancer Epidemiology and Biology

描述（由申请人提供）：子宫内膜癌是美国最常见的妇科癌症，预计今年将有近5万例新病例和8,000多例死亡。近年来，癌症的发病率和数量都有所增加，随着人口老龄化和预期寿命的增加，这些趋势可能会继续下去。此外，死亡率有所上升。在了解这一疾病的流行病学和生物学方面取得了重大进展，但这些领域的研究一直在平行进行，尚未整合。在其他领域，知识的差距仍然存在，阻碍了减少子宫内膜癌的影响。本次研讨会将汇集来自流行病学、生物学、病理学、心理学、卫生政策和临床实践领域的专家，交流知识和想法。研讨会的具体目标是在研究人员之间达成共识，以确定可以解决的高优先级研究问题，并对降低子宫内膜癌的发病率和改善其结局产生切实影响。我们计划于2014年3月在马萨诸塞州波士顿举行为期两天的研讨会。将有八个关于具体专题的会议，每个会议有两到四个发言者和一个讨论领导人。在第二天结束时，将有小组讨论会议，以制定未来研究的优先事项，这些研究将确定对降低风险和提高这种常见疾病的生存率影响最大的项目。

DESCRIPTION (provided by applicant): Endometrial cancer is the most common gynecologic cancer in the U.S., with nearly 50,000 new cases and more than 8,000 deaths expected this year. Both the incidence rate and the number of cancers have grown in recent years, and it is likely that these trends will continue as the population ages and life expectancy increases. Further, the mortality rate has increased. Substantial progress has been made in understanding both the epidemiology and the biology of this disease, but research in these areas has proceeded down parallel tracks and has yet to be integrated. In other areas, gaps in knowledge remain that stand in the way of reducing the impact of endometrial cancer. This symposium will bring together experts from the fields of epidemiology, biology, pathology, psychology, health policy, and clinical practice to exchange knowledge and ideas. The specific goal of the symposium is to reach consensus among researchers to identify high-priority research questions that can be addressed and that will have a tangible impact on reducing incidence of and improving outcomes for endometrial cancer. We plan a two-day symposium to be held in Boston, MA, in March 2014. There will be eight sessions on specific topics, each with two to four speakers and a discussion leader. At the end of the second day, there will be group discussion sessions to develop priorities for future research that will identify the programs that will have te greatest impact on reducing risk and improving survival from this common disease.